Eisai
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eisai sits in the top decile of US sponsors by registered trial count (#121 of 15,742 sponsors by registered trial count).
Eisai: 287 sponsored US clinical trials, 5 recruiting.
Eisai sponsors 287 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 243 completed. 67 of these trials are in Phase 3-4 (later-stage) and 214 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Subjects, with 6 trials.
Top-decile sponsor footprint
Eisai ranks in the top decile of sponsors by registered trial count (#121 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
243 of 273 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
287 total, page 5 of 6
Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)
NCT00592774
The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility
NCT00571064
Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
NCT00592904
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
NCT00603902
Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
NCT00566501
Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer
NCT00525590
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
NCT00603291
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome
NCT00570128
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome
NCT00548587
Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT
NCT00566462
A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors
NCT00309179
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease
NCT00312052
Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis
NCT00539929
Neural Correlates In Mild Alzheimer's Disease
NCT00477659
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
NCT00478205
An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy
NCT00505284
Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003
NCT00625443
Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
NCT00448539
Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT00441090
A Study of E2007 In Patients With Parkinson's Disease
NCT00427011
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00388726
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
NCT00381173
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
NCT00395135
A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors
NCT00268905
4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures
NCT00368472
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
NCT00282399
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
NCT00337103
Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
NCT00368108
ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis
NCT00334828
A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors
NCT00165802
A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.
NCT00327392
An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Flexible Bronchoscopy
NCT00306722
A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms
NCT01286194
An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Colonoscopy
NCT00261599
Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
NCT00306735
Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures
NCT00334958
A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment
NCT00934375
Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
NCT00278993
A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies
NCT00130169
EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)
NCT00230568
Trial of Decitabine in Patients With Acute Myeloid Leukemia
NCT00260832
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
NCT00236184
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
NCT00236197
A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
NCT00246090
A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations
NCT00165789
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
NCT00132496
A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix
NCT00264732
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
NCT00121680
GPI 15715 For Sedation in the Intensive Care Unit (ICU) Setting
NCT00125398
Study of AQUAVAN® Injection (AQUAVAN; Fospropofol Disodium) for Sedation During Colonoscopy
NCT00125424
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 122 |
| Phase 2 | 92 |
| Phase 3 | 52 |
| Phase 4 | 15 |
Therapeutic Areas
What is open in the Eisai pipeline
5 recruiting of 287 indexed (2% open); 243 completed (85%).
Phase mix: 67 late (III/IV) vs 214 early (I/II) (early-phase heavy).
Top condition: Healthy Subjects (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eisai: open-pipeline peers nationwide
Peers matched on 287 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Eisai sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 287 trials (± recruiting share)
- University of Missouri-Columbia · 291 trials · 19% recruiting
- Thomas Jefferson University · 292 trials · 18% recruiting
- University of Michigan Rogel Cancer Center · 292 trials · 15% recruiting
- Kaiser Permanente · 294 trials · 7% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Medtronic Cardiac Rhythm and Heart Failure · 2% recruiting · 115 trials
- Bausch & Lomb Incorporated · 2% recruiting · 174 trials
- Lexicon Pharmaceuticals · 2% recruiting · 56 trials
- Alcon Research · 2% recruiting · 275 trials
Related
What to do with this Eisai page
287 registered trials is a research-attention snapshot, not an endorsement of Eisai or any single study.
- 5 of Eisai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy Subjects is the condition Eisai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Subjects trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Eisai pipeline card: 287 registered trials from official public datasets.Report a data error.